1068 related articles for article (PubMed ID: 18440693)
61. The levonorgestrel intrauterine system is an effective treatment in women with abnormal uterine bleeding and anticoagulant therapy.
Vilos GA; Tureanu V; Garcia M; Abu-Rafea B
J Minim Invasive Gynecol; 2009; 16(4):480-4. PubMed ID: 19573825
[TBL] [Abstract][Full Text] [Related]
62. Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women.
Lehtovirta P; Paavonen J; Heikinheimo O
Contraception; 2007 Jan; 75(1):37-9. PubMed ID: 17161122
[TBL] [Abstract][Full Text] [Related]
63. Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception.
Rose S; Chaudhari A; Peterson CM
Adv Drug Deliv Rev; 2009 Aug; 61(10):808-12. PubMed ID: 19445984
[TBL] [Abstract][Full Text] [Related]
64. Progestin-releasing intrauterine systems and leiomyoma.
Kaunitz AM
Contraception; 2007 Jun; 75(6 Suppl):S130-3. PubMed ID: 17531604
[TBL] [Abstract][Full Text] [Related]
65. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
[TBL] [Abstract][Full Text] [Related]
66. [Effects of levonorgestrel-releasing intrauterine system on pain and recurrence associated with endometriosis and adenomyosis].
Deng S; Lang JH; Leng JH; Liu ZF; Sun DW; Zhu L
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):664-8. PubMed ID: 17199919
[TBL] [Abstract][Full Text] [Related]
67. Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study.
Arnes M; Hvingel B; Orbo A
Anticancer Res; 2014 May; 34(5):2319-24. PubMed ID: 24778038
[TBL] [Abstract][Full Text] [Related]
68. Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study.
Gallos ID; Devey J; Ganesan R; Gupta JK
Gynecol Oncol; 2013 Jul; 130(1):58-63. PubMed ID: 23603367
[TBL] [Abstract][Full Text] [Related]
69. User satisfaction with a levonorgestrel-releasing intrauterine system (LNG-IUS): data from an international survey.
Römer T; Linsberger D
Eur J Contracept Reprod Health Care; 2009 Dec; 14(6):391-8. PubMed ID: 19929641
[TBL] [Abstract][Full Text] [Related]
70. Menstrual blood loss in women using the frameless FibroPlant LNG-IUS.
Andrade A; Wildemeersch D
Contraception; 2009 Feb; 79(2):134-8. PubMed ID: 19135571
[TBL] [Abstract][Full Text] [Related]
71. The levonorgestrel intrauterine system: more than a contraceptive.
Andersson K
Eur J Contracept Reprod Health Care; 2001 Jan; 6 Suppl 1():15-22. PubMed ID: 11336429
[TBL] [Abstract][Full Text] [Related]
72. Five-year follow-up of levonorgestrel-releasing intrauterine system versus thermal balloon ablation for the treatment of heavy menstrual bleeding: a randomized controlled trial.
Silva-Filho AL; Pereira Fde A; de Souza SS; Loures LF; Rocha AP; Valadares CN; Carneiro MM; Tavares RL; Camargos AF
Contraception; 2013 Apr; 87(4):409-15. PubMed ID: 23228505
[TBL] [Abstract][Full Text] [Related]
73. The levonorgestrel intrauterine system in nulliparous women.
Prager S; Darney PD
Contraception; 2007 Jun; 75(6 Suppl):S12-5. PubMed ID: 17531602
[TBL] [Abstract][Full Text] [Related]
74. Managing drug-resistant essential menorrhagia without hysterectomy.
Hurskainen R
Best Pract Res Clin Obstet Gynaecol; 2006 Oct; 20(5):681-94. PubMed ID: 16731045
[TBL] [Abstract][Full Text] [Related]
75. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review.
Wan YL; Holland C
Climacteric; 2011 Dec; 14(6):622-32. PubMed ID: 22017273
[TBL] [Abstract][Full Text] [Related]
76. Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
Wildemeersch D; Schacht E; Wildemeersch P
Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):192-8. PubMed ID: 11848648
[TBL] [Abstract][Full Text] [Related]
77. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1.
Pakarinen P; Lähteenmäki P; Rutanen EM
Acta Obstet Gynecol Scand; 1999 May; 78(5):423-8. PubMed ID: 10326889
[TBL] [Abstract][Full Text] [Related]
78. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study.
Short M; Dallay D; Omokanye S; Hanisch JU; Inki P
Eur J Contracept Reprod Health Care; 2012 Feb; 17(1):79-88. PubMed ID: 22200172
[TBL] [Abstract][Full Text] [Related]
79. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P
Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315
[TBL] [Abstract][Full Text] [Related]
80. Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study.
Sletten ET; Arnes M; Vereide AB; Ørbo A
Anticancer Res; 2018 May; 38(5):2883-2889. PubMed ID: 29715112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
